PPARδ agonist 13
PPARδ agonist 13 is a potent, selective and orally active PPARδ agonist with an EC50 values of 0.50 nM. PPARδ agonist 13 binds to the PPARδ ligand-binding pocket and upregulates PPARδ target gene expression. PPARδ agonist 13 inhibits renal fibroblast activation, restores fatty acid oxidation, and attenuates TGF-β1-induced renal fibroblast activation. PPARδ agonist 13 exhibits anti-renal fibrosis effects in a mouse model of unilateral ureteral obstruction. PPARδ agonist 13 can be used for the research of renal fibrosis.
For research use only. We do not sell to patients.
- CAS No.: 3056618-93-7
- Formula: C27H24F3N2NaO4
- Molecular Weight:520.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PPARδ 0.5 nM (EC50) |
PPARα >10000 nM (EC50) |
PPARγ >10000 nM (EC50) |
In Vitro
PPARδ agonist 13 (Compound 16a) (10-1000 nM; 6 h) dose-dependently upregulates PPARδ target gene expression in HK2 cells[1].
PPARδ agonist 13 (0.2-5 μM; 16 h) shows high selectivity for PPARδ in Cos-7 cells, with only weak PPARγ agonism observed at the highest tested concentration of 5 μM[1].
PPARδ agonist 13 (1-30 μM; 3 min) directly interacts with purified PPARδ LBD protein, as demonstrated by dose-dependent reduction of ANS fluorescence[1].
PPARδ agonist 13 (0.3-30 μM) does not inhibit hERG potassium channels in hERG knock-in HEK293 cells, indicating low cardiovascular risk[1].
PPARδ agonist 13 (2.5-10 nM; 23 h) dose-dependently attenuates TGF-β1-induced activation of NRK-49F renal fibroblasts, reducing α-SMA and fibronectin expression at concentrations of 2.5 and 10 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human renal proximal tubule HK2 cells
-
Concentration:10, 100, 1000 nM
-
Incubation Time:6 h
-
Result:Dose-dependently upregulated the expression of PPARδ target genes ANGPTL4, PDK4, and CPT1A in HK2 cells.
-
Cell Line:NRK-49F cells
-
Concentration:2.5, 10 nM
-
Incubation Time:23 h (after 1 h TGF-β1 pre-treatment)
-
Result:Dose-dependently suppressed the TGF-β1-induced expression of fibrotic markers α-SMA and fibronectin in NRK-49F cells.
Parmacokinetics
In Vivo
PPARδ agonist 13 (100 mg/kg for 14 days or 2000 mg/kg single dose; i.g.) shows low toxicity in C57BL/6JNifdc mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6JNifdc (male, 7-8 weeks old, ~22 g, nilateral ureteral obstructio model)[1]
-
Dosage:3 mg/kg; 10 mg/kg
-
Administration:I.g.; daily; 13 days
-
Result:Relieved UUO-induced tubular atrophy and dilation.
Significantly reduced UUO-induced collagen accumulation and decreased protein expression of collagen I and collagen III.
Potently downregulated UUO-induced upregulation of α-SMA protein levels and mRNA expression of fibrotic genes (Acta2, Col1a1, Col3a1, Col4a1, Fn1, Vim, Tgfb1, Ctgf).
Reduced UUO-induced renal interstitial inflammatory cell infiltration and dose-dependently suppressed elevated mRNA levels of pro-inflammatory cytokines/chemokines (Tnf, Il1b, Il6, Ccl4, Ccl5).
Decreased protein levels of phosphorylated NF-κB p65 and phosphorylated JNK, and increased the antiapoptotic Bcl-2 to pro-apoptotic Bax protein ratio to mitigate UUO-induced renal apoptosis.
Dose-dependently restored UUO-downregulated mRNA expression of fatty acid oxidation-related genes (Cpt1a, Cpt2, Acadm, Acadvl, Acads, Ppargc1a) in kidney tissue.
Chemical Information
-
CAS No. 3056618-93-7
-
Molecular Weight 520.48
-
Formula C27H24F3N2NaO4
-
SMILES
O=C(CCCCCOC1=C(CN2C(C3=CC=C(C=C3)OC(F)(F)F)=NC4=C2C=CC=C4)C=CC=C1)O[Na]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)